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EDITORIAL
Squamous carcinoma of the lung: 
still a long and winding road to 
successful treatment
Paolo Bironzo1 & Giorgio Vittorio Scagliotti*,1
Lung cancer is the leading cause of can-
cer-related death worldwide, accounting 
for approximately 1.4 million deaths in 
2010 in the USA, according to the SEER 
d atabase [1].
Approximately 85% of newly diagnosed 
lung tumors are non-small-cell lung cancer 
(NSCLC) and, among them, 20–30% are 
squamous cell lung cancer (SQCLC). The 
incidence of this subtype has now been 
surpassed by adenocarcinoma, reflecting 
trends in reduced tobacco exposure with 
the introduction of filtered and low-tar 
content cigarettes, as well as changes in 
cigarette smoke inhalation patterns [2].
The diagnosis of SQCLC is currently 
performed by light microscopy and relies 
on the presence of keratinization and/or 
intracellular bridges. With the increasing 
need of a correct histological diagnosis in 
order to choose the right therapeutic regi-
men, the dichotomy between small-cell 
lung cancer and NSCLC became obso-
lete. For such reasons when in poorly dif-
ferentiated lung carcinomas there is no 
clear-cut cellular differentiation at light 
microscopy, which account for 20–30% 
of cases, a panel of immunohistochem-
istry (IHC) markers has been shown to 
increase the likelihood of an appropriate 
subtyping. This panel includes at least 
cytokeratin CK7, CK5, TTF-1 and p63, 
as demonstrated by a retrospective study 
performed on fine-needle aspiration cytol-
ogy cell blocks [3]. Another marker, p40, an 
antibody that recognizes the ΔNp63-a p63 
isoform, is equivalent to p63 in sensitivity 
but markedly superior to p63 in specific-
ity, which eliminates the potential pitfall 
of misinterpreting a p63-positive adeno-
carcinoma or unsuspected lymphoma as 
a SCC [4].
Current available treatment options 
for advanced SQCLC rely only on sys-
temic cytotoxic chemotherapy. Patients 
with a good performance status (Eastern 
Cooperative Oncology Group performance 
status 0–1) should receive a platinum agent, 
cisplatin (preferentially) or carboplatin, 
plus a third-generation drug (taxanes, 
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“…as the squamous cell lung 
cancer treatment landscape 
evolves many new therapeutic 
issues have arisen at the 
same time.” 
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vinorelbine or gemcitabine). Eastern Cooperative 
Oncology Group performance status 2 patients 
are often treated with single-agent chemotherapy, 
although carboplatin-based doublet could be also 
considered. Finally, best supportive care (BSC) 
represents the only option for PS 3–4 patients [5].
Several studies (for review, see [6]) have shown 
an inferior activity of pemetrexed in combina-
tion with cisplatin in SQCLC and this agent 
is currently not licensed for the treatment of 
this type of tumor. The histology-related activ-
ity of pemetrexed has been related to a differ-
ent expression of thymidylate synthase (TS), 
one of the main enzymes of the folate pathway 
targeted by pemetrexed, with expression being 
higher in SQCLC and lower in nonsquamous 
NSCLC [7]. Other markers of chemoresistance 
such as ERCC1 and BRCA1 equally show higher 
e xpression in SQCLC than other histotypes [8].
A large Phase III study that compared carbo-
platin combined with albumin-bound paclitaxel 
(nab-PC) or paclitaxel demonstrated a signifi-
cantly higher ORR with nab-PC than paclitaxel 
in the overall population (33 vs 25%; p = 0.005) 
and in patients with squamous histology (41 vs 
24%; p < 0.001), while nab-PC was as effec-
tive as paclitaxel in patients with nonsquamous 
 histology (26 vs 25%; p = 0.808) [9].
Platinum chemotherapy with poly(ADP-
ribose) polymerase (PARP) inhibitors have been 
studied in clinical trials. Preclinical observations 
have shown that PARP inhibitors preferentially 
kill neoplastic cells and induce complete or par-
tial regression in various human tumor xeno-
grafts in nude mice treated with platinum agents 
[10]. However, PARP activity in DNA repair is 
not fully clear [11], and as a result the biological 
mechanisms by which PARP inhibitors sensitize 
cancer cells to platinum chemotherapy remain 
to be resolved.
Currently the role of targeted therapies in 
SQCLC remains elusive. Bevacizumab, a mono-
clonal antibody against VEGF, is an established 
treatment option combined with chemotherapy 
in nonsquamous advanced NSCLC only. Such 
restriction is related to life-threatening or fatal 
episodes of hemoptysis in bevacizumab-treated 
patients with SQCLC, as observed in one of 
the early Phase II trials [12], and the drug is not 
currently licensed for SQCLC. Several multitar-
geted, antiangiogenic agents including sorafenib, 
motesanib and nintedanib have been studied 
in clinical trials for patients with advanced 
NSCLC. For most of these agents antitumor 
activity has not been seen in SQCLC and occa-
sionally only additive toxicity has been reported 
(for review see [13]).
Nintedanib, which inhibits VEGF receptor 
(VEGFR), PDGF receptor (PDGFR) and FGF 
receptor (FGFR), has been extensively inves-
tigated. The LUME-Lung 1 study comparing 
docetaxel plus nintedanib versus docetaxel plus 
placebo as second-line treatment in NSCLC 
patients and in SQCLC showed only a small 
statistically significant improvement in pro-
gression-free survival and no effect on overall 
survival [14].
SQCLC lacks EGF receptor (EGFR) muta-
tions and ALK gene fusions, and the occasional 
detection of these mutations in SQCLC is due 
to challenges with differential diagnosis with 
adenosquamous carcinoma and adenocarcinoma, 
an issue mostly resolved by incorporating IHC 
markers [15]. Independently from the abovemen-
tioned issue, when EFGR mutations are detected 
in SQCLC they are in almost invariably in never 
smokers.
In a Phase III trial (FLEX) a statistically 
nonsignificant correlation in SQCLC between 
increased survival and chemotherapy plus cetux-
imab, a monoclonal antibody against EGFR, 
was observed in the subgroup of patients with 
SQCLC [16] and high EGFR expression was asso-
ciated with survival in the study population [17].
When compared with adenocarcinoma, 
SQCLC is characterized by a more complex 
genetic profile. Chromosome 3q amplification 
and chromosome 3p and 9p deletions have 
been frequently reported. In particular, SOX2 
is amplified in approximately 20% of SQCLC 
series and, by contrast, FOXP1 is inactivated in 
4% of tumors [18]. The TCGA Cancer Genome 
Atlas (TCGA) found that the genes signifi-
cantly mutated include TP53, CDKN2A, PTEN, 
PIK3CA, KEAP1, MLL2, HLA-A, NFE2L2, 
NOTCH1 and RB1 [18]. Smokers affected by 
SQCLC frequently carry DDR2 and FGFR2 
mutations, while EGFR, MET and PIK3CA 
mutations are prevalent in never-smokers [19]. 
Among mutations, the most interesting from 
a therapeutic point of view are represented by 
MDM2, a negative regulator of p53 [20], PIK3CA 
and PTEN, DDR2, FGFR1, MLL2 and ERBB2.
Constitutive activation of FGFR1 by gene 
amplification, translocation or mutation is asso-
ciated with various malignancies such as breast 
cancer or myeloproliferative diseases. It has been 
recently reported that FGFR1 amplification 
“While our knowledge of 
tumors genetics and 
microenvironment evolve 
rapidly, the challenge is to 
correctly put in the right 
place each piece of the 
evolving puzzle to 
gradually improve patient 
outcome.”
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occurs in 20% of SQCLC, and preclinical tests 
have shown that these alterations are therapeu-
tically tractable. These findings make FGFR1 
amplification a potential biomarker for lung 
cancer treatment [21].
The NRF2 pathway, involved in cell response 
to oxidative stress, and the Eph-ephrin signal-
ing system, especially related to EPHB3 over-
expression, have been detected in SQCLC, but 
the development of effective targeting agents is 
lacking [22,23].
Several checkpoint receptors expressed on T 
cells modulate the immune response as part of 
normal physiological processes to maintain self-
tolerance, prevent autoimmunity, suppress inap-
propriate responses to host antigens and protect 
nontumor tissues from damage [24]. Tumors can 
exploit these immune checkpoint pathways to 
evade the immune response and develop resist-
ance against attack from the immune system. Two 
such pathways with the potential for therapeutic 
anticancer targeting include PD-1 and CTLA-4.
Monoclonal antibodies (mAbs) against PD-1 
and PDL-1 demonstrated activity in both pre-
treated and naive patients. In a Phase I trial 
nivolumab, a fully human mAb directed against 
the cytotoxic T-cell protein PD1, led to a 23% 
response rate in previously treated SQCLC 
patients [25]. In a heavily pretreated group of 
patients the median OS was 10.1 months, with 
a 1-year OS of 42% and a 2-year OS of 24% 
[26]. Another anti-PD1 mAb, pembrolizumab, 
was tested in a Phase II trial in previously 
untreated PD-L1-positive NSCLC patients. In 
the 42 evaluable patients the objective response 
rate by immune-related response criteria (irRC) 
was 36% [27]. Two mAbs that target PD-L1, 
MPDL3280A and MEDI4736, have recently 
been tested, reporting comparable results, as 
reported with nivolumumab and pembroli-
zumab [28,30]. The immunohistochemistry score 
for PD-L1 expression directly correlated with 
response rate as smoking status, with 26% of 
responses in current or former smokers versus 
10% in never smokers [29].
In conclusion, as the SQCLC treatment 
landscape evolves many new therapeutic issues 
have arisen at the same time. Molecular altera-
tions proven to be predictive tools in oncogene-
addicted adenocarcinomas do not apply to 
SQCLC, probably as a consequence of its more 
complex genetic profile. However, at the same 
time the expanding role of next-generation 
sequencing and its vastly reduced cost paves 
the way for a more appropriate use of targeted 
agents, possibly leading to better results even in 
SQCLC. Moreover, the immunotherapy, with 
its promising results, has opened exciting new 
roads that will be thoroughly explored in the 
near future, both in the advanced and early dis-
ease setting. While our knowledge of tumors 
genetics and microenvironment evolve rapidly, 
the challenge is to correctly put in the right place 
each piece of the evolving puzzle to gradually 
improve patient outcome.
Financial & competing interests disclosure
GV Scagliotti has received honoraria from Eli Lilly, 
AstraZeneca, Roche, Pfizer and Clovis Oncology. The 
authors have no other relevant affiliations or financial 
involvement with any organization or entity with a finan-
cial interest in or financial conflict with the subject matter 
or materials discussed in the manuscript apart from those 
disclosed.
No writing assistance was utilized in the production of 
this manuscript.
References
1 National Cancer Institute.  
http://seer.cancer.gov/
2 Siegel R, Naishadham D, Jemal A. Cancer 
statistic 2013. CA Cancer J. Clin. 63, 11–30 
(2013).
3 Righi L, Graziano P, Fornari A et al. 
Immunhistochemical subtyping of nonsmall 
cell lung cancer not otherwise specified in 
fine-needle aspiration cytology: a retrospective 
study of 103 cases with surgical correlation. 
Cancer 117, 3416–3423 (2011).
4 Bishop JA, Teruya-Feldstein J, Westra WH 
et al. p40(ΔNp63) is superior to p63 for the 
diagnosis of pulmonary squamous cell 
carcinoma. Mod. Pathol. 25, 405–415 (2012).
5 Reck M, Popat S, Reinmuth N et al. 
Metastatic non-small-cell lung cancer 
(NSCLC): ESMO Clinical Practice 
Guidelines for diagnosis, treatment and 
follow-up. Ann. Oncol. doi:10.1093/annonc/
mdu199 (2014) (Epub ahead of print).
6 Scagliotti G, Brodowicz T, Shepherd FA et al. 
Treatment-by-histology interaction analyses 
in three Phase III trials show superiority of 
pemetrexed in nonsquamous non-small cell 
lung cancer. J. Thorac. Oncol. 6, 64–70 
(2011).
7 Ceppi P, Volante M, Saviozzi S et al. 
Squamous cell carcinoma of the lung 
compared with other histotypes shows higher 
messenger RNA and protein levels for 
thymidylate synthase. Cancer 107, 1589–1596 
(2006).
8 Bonanno L, Favaretto A, Rosell R. Platinum 
drugs and DNA repair mechanisms in lung 
cancer. Anticancer Res. 34, 493–501 (2014).
9 Socinski MA, Bondarenko I, Karaseva NA 
et al. Weekly nab-paclitaxel in combination 
with carboplatin versus solvent-based 
paclitaxel plus carboplatin as first-line therapy 
in patients with advanced non-small-cell lung 
cancer: final results of a Phase III trial. J Clin. 
Oncol. 30, 2055–2062 (2012).
10 Miknyoczki SJ, Jones-Bolin S, Pritchard S 
et al. Chemopotentiation of temozolomide, 
irinotecan, and cisplatin activity by 
CEP-6800, a poly(ADP-ribose) polymerase 
Lung Cancer Manag. (2014) 3(5)368
Editorial Bironzo & Scagliotti
future science group
inhibitor. Mol. Cancer Ther. 2, 371–382 
(2003).
11 Ahel I, Ahel D, Matsusaka T et al. Poly 
(ADP-ribose)-binding zinc finger motifs in 
DNA repair/checkpoint proteins. Nature 451, 
81–85 (2008).
12 Johnson DH, Fehrenbacher L, Novotny WF 
et al. Randomized Phase II trial comparing 
bevacizumab plus carboplatin and paclitaxel 
with carboplatin and paclitaxel alone in 
previously untreated locally advanced or 
metastatic non-small cell lung cancer. J. Clin. 
Oncol. 22, 2184–2191 (2004).
13 Scagliotti G, Govindan R. Targeting 
angiogenesis with multitargeted tyrosine 
kinase inhibitors in the treatment of 
non-small cell lung cancer. Oncologist 15, 
436–446 (2010)
14 Reck M, Kaiser R, Mellemgaard A et al. 
Docetaxel plus nintedanib versus docetaxel 
plus placebo in patients with previously treated 
non-small-cell lung cancer (LUME-Lung 1): a 
Phase 3, double-blind, randomised controlled 
trial. Lancet Oncol. 15, 143–155 (2014).
15 Rekhtman N, Paik PK, Arcila ME et al. 
Clarifying the spectrum of driver oncogene 
mutations in biomarker-verified squamous 
carcinoma of lung: lack of EGFR/KRAS and 
presence of PIK3CA/AKT1 mutations. Clin. 
Cancer Res. 18, 1167–1176 (2012).
16 Pirker R, Pereira JR, Szczesna A et al. 
Cetuximab plus chemotherapy in patients 
with advanced non-small cell lung cancer 
(FLEX): an open-label randomised Phase III 
trial. Lancet 373, 1525–1531 (2009).
17 Pirker R, Pereira JR, von Pawel J et al. EGFR 
expression as a predictor of survival for 
first-line chemotherapy plus cetuximab in 
patients with advanced non-small-cell lung 
cancer: analysis of data from the Phase 3 
FLEX study. Lancet Oncol. 13, 33–42 (2012).
18 Hammerman PS, Hayes DN, Wilkerson MD 
et al. Comprehensive genomic 
characterization of squamous cell lung 
cancers. Nature 489, 519–525 (2012).
19 An SJ, Chen ZH, Su J et al. Identification of 
enriched driver gene alterations in subgroups 
of non-small cell lung cancer patients based 
on histology and smoking status. PLoS ONE 
7, e40109 (2012).
20 Wade M, Li YC, Wahl GM. MDM2, 
MDMX and p53 in oncogenesis and cancer 
therapy. Nat. Rev. Cancer 13, 83–96 (2012).
21 Dienstmann R, Rodon J, Prat A et al. 
Genomic aberrations in the FGFR pathway: 
opportunities for targeted therapies in solid 
tumors. Ann. Oncol. 25, 552–563 (2014).
22 Sasaki H, Suzuki A, Shitara M et al. 
Genotype analysis of the NRF2 gene mutation 
in lung cancer. Int. J. Mol. Med. 31(5), 
1135–1138 (2013).
23 Li JJ, Xie D. The roles of and therapeutic 
potentials of Ephs and ephrins in lung cancer. 
Exp. Cell Res. 319, 152–159 (2013).
24 Pardoll DM. The blockade of immune 
checkpoints in cancer immunotherapy. Nat. 
Rev. Cancer 12, 252–264 (2012).
25 Brahmer JR, Horn L, Antonia SJ et al. Survival 
and long-term follow-up of the Phase I trial of 
nivolumab (anti-PD-1; BMS-936558; 
ONO-4538) in patients (PTS) with previously 
treated advanced non-small cell lung cancer 
(NSCLC). Presented at: 2013 ASCO Annual 
Meeting. Chicago, IL, USA, 31 May–4 June 
2013 (Abstract 8030).
26 Brahmer JR, Horn L, Antonia SJ et al. 
Nivolumab (anti-PD-1; BMS-936558; 
ONO-4538) in patients with non-small cell 
lung cancer (NSCLC): overall survival and 
long-term safety in a Phase 1 trial. Presented 
at: 15th World Conference on Lung Cancer. 
Sydney, Australia, 27–30 October 2013 
(Abstract MO18.03).
27 Rizvi NA, Garon EB, Patnaik A et al. Safety 
and clinical activity of MK-3475 as initial 
therapy in patients with advanced non-small 
cell ling cancer (NSCLC). Presented at: 2014 
ASCO Annual Meeting. Chicago, IL, USA, 
30 May–3 June 2014 (Abstract 8007).
28 Horn L, Herbst RS, Spigel D et al. An 
analysis of the relationship of clinical activity 
to baseline EGFR status, PD-L1 expression 
and prior treatment history in patients with 
non-small cell lung cancer (NSCLC) 
following PD-L1 blockade with 
MPDL3280A (anti-PDL1). Presented at: 
15th World Conference on Lung Cancer. 
Sydney, Australia, 27–30 October 2013 
(Abstract MO18.01).
29 Brahmer JR, Rizvi NA, Lutzky J et al. 
Clinical activity and biomarkers of 
MEDI4736, an anti-PD-L1 antibody, in 
patients with NSCLC. Presented at: 
2014 ASCO Annual Meeting. Chicago, IL, 
USA, 30 May–3 June 2014 (Abstract 8021).
30 Spigel DR, Gettinger SN, Horn L et al. 
Clinical Activity, safety, and biomarkers of 
MPDL3280A, an engineered PD-L1 antibody 
in patients with localiy advanced or metastatic 
non-small cell lung cancer (NSCLC). 
Presented at: 2013 ASCO Annual Meeting. 
Chicago, IL, USA, 31 May–4 June 2013 
(Abstract 8008).
